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A candidate live-virus vaccine strain of Venezuelan equine encephalitis virus (VEE) was configured as a
replication-competent vector for in vivo expression of heterologous immunogens. Three features of VEE recom-
mend it for use as a vaccine vector. (i) Most human and animal populations are not already immune to VEE,
so preexisting immunity to the vector would not limit expression of the heterologous antigen. (ii) VEE
replicates first in local lymphoid tissue, a site favoring the induction of an effective immune response. (iii)
Parenteral immunization of rodents and humans with live, attenuated VEE vaccines protects against mucosal
challenge, suggesting that VEE vaccine vectors might be used successfully to protect against mucosal patho-
gens. Upon subcutaneous (s.c.) inoculation into the footpad of mice, a VEE vector containing the complete
influenza virus hemagglutinin (HA) gene expressed HA in the draining lymph node and induced anti-HA
immunoglobulin G (IgG) and IgA serum antibodies, the levels of which could be increased by s.c. booster
inoculation. When immunized mice were challenged intranasally with a virulent strain of influenza virus,
replication of challenge virus in their lungs was restricted, and they were completely protected from signs of
disease. Significant reduction of influenza virus replication in the nasal epithelia of HA vector-immunized mice
suggested an effective immunity at the mucosal surface. VEE vaccine vectors represent an alternative vacci-
nation strategy when killed or subunit vaccines are ineffective or when the use of a live attenuated vaccine might
be unsafe.
Vaccination has proved to be the most effective means of
controlling viral disease, especially when live attenuated vac-
cines, such as those for smallpox, poliomyelitis, and measles,
have been employed. In these instances, virus mutants repli-
cate within the vaccinated host without causing disease, while
inducing protective and long-lasting immunity to the naturally
occurring pathogenic virus. This approach has been extended
by using vaccine virus genomes as vectors to express the genes
of other pathogens in vivo (2, 12, 20, 25). In this report, we
describe the construction of an expression system based on a
candidate Venezuelan equine encephalitis virus (VEE) vaccine
strain and its ability to express a heterologous gene both in
vitro and in vivo. The influenza virus hemagglutinin (HA) gene
was used in this study because it afforded a stringent test of
mucosal protection in the mouse. Mice vaccinated with the
VEE HA vector not only were protected against clinical dis-
ease following intranasal influenza virus challenge, but also
exhibited resistance to influenza virus replication in the lung
and at mucosal surfaces of the upper respiratory tract.
VEE is a member of the Alphavirus genus, a group which
includes Sindbis virus and Semliki Forest virus as prototypes
(35). Several properties of alphaviruses have made them useful
tools for high-level expression of foreign genes both in cell
culture and in animals (21, 23, 24, 28, 29, 37, 39). These viruses
can infect a wide range of vertebrate and invertebrate cells to
initiate a prolific, cytoplasmic replication cycle. Their single-
stranded positive-sense RNA genomes (between 11,000 and
12,000 nucleotides) are infectious, as are genome replicas de-
rived from full-length cDNA clones (35). Self-replicating RNA
genomes serve as mRNA for an enzyme complex with both
RNA replicase and transcriptase activities, and transcription of
a subgenomic mRNA for the structural proteins is driven by a
very strong, highly conserved promoter sequence. Taking ad-
vantage of this high-level promoter, alphavirus expression vec-
tors either contain a foreign gene in place of the viral structural
protein genes (37) or contain a duplicate subgenomic mRNA
promoter that drives expression of a foreign gene (13).
Three biological features of VEE suggest that it could be an
unusually effective in vivo expression vector for vaccination
with heterologous gene products. First, parenteral immuniza-
tion of rodents and humans with live, attenuated VEE vaccines
results in protection not only against parenteral challenge but
also against intranasal (i.n.) and aerosol challenges (5, 7, 16,
17). This predicts that a delivery system based on a VEE
vaccine could induce protection from invasion at mucosal sur-
faces, which are important routes of entry for many pathogens,
including human immunodeficiency virus. Second, in contrast
to most other alphaviruses, VEE replicates first in the lymph
nodes draining the site of inoculation (10, 11, 15), where high-
level synthesis of a heterologous antigen might result in effi-
cient immunization. Finally, and in contrast to viral vectors
based on vaccinia virus or vaccine strains of adenovirus and
poliovirus, most human and animal populations are not al-
ready immune to VEE. Therefore, in vivo expression of a
heterologous immunogen from a VEE-based vaccine vector
would not be limited by prior immunity to the vector itself.
MATERIALS AND METHODS
Clones and viruses. Plasmid pV3014, a derivative of the full-length cDNA
clone of the virulent Trinidad donkey strain of VEE with two attenuating mu-
tations (E2 [Lys-209] and E1 [Thr-272]; described in references 8 and 11), was
altered to allow expression of heterologous genes. A duplicate 26S RNA pro-
moter followed by a unique ClaI site was inserted immediately downstream of
the E1 gene by oligonucleotide-directed mutagenesis of a subclone of the struc-
tural protein genes in M13 (18). The promoter sequence and its ability to
function in an abnormal context were predicted from previous work with Sindbis
virus (13, 19). The VEE structural gene region with the auxiliary 26S subgenomic




RNA promoter was subcloned into pUC118. The multiple cloning region of the
Cla12 adaptor plasmid (14) (the kind gift of S. Hughes, National Cancer Insti-
tute), flanked by ClaI sites, was inserted into the unique ClaI site to form a
shuttle vector. The cloned cDNA of the complete HA gene from influenza virus
strain PR/8/34, type H1N1, kindly supplied by P. Palese, Mt. Sinai School of
Medicine, New York, was inserted into the multiple cloning region of the shuttle
vector. The HA gene was then transferred by using ClaI into the full-length VEE
vector clone. Infectious RNA genome equivalents were transcribed in vitro from
linearized plasmids with T7 RNA polymerase and used in electroporation of
baby hamster kidney (BHK) cells to produce stocks of progeny virus (9, 22).
An egg-grown stock of influenza virus strain PR/8/34, generously supplied by
H. van Campen, University of Wyoming, Laramie, was used for i.n. challenge of
mice. A similar virus preparation grown from ATCC seed stock VR-95 in em-
bryonated eggs was used for neutralization assays and BHK cell infections.
Immunization and challenge of mice. Adult (4- or 6-week old), female CD-1
mice (Charles River) were put under light anesthesia by inhalation of Metofane
(Pitman-Moore) and immunized by subcutaneous (s.c.) inoculation of 104 PFU
of vector without insert or HA vector in a 10-ml volume of diluent (phosphate-
buffered saline [PBS] containing 1% donor calf serum) into each rear footpad.
Mock-immunized controls received diluent alone. Booster inoculations were
done 3 weeks postimmunization and were identical to the initial immunization
except that the total dose of HA vector or vector alone was 2 3 105 PFU.
Twenty-one days following the primary immunization or 18 days following the
boost, a challenge dose of 105 50% egg infectious doses of egg-grown influenza
virus strain PR/8/34 in a total volume of 20 ml of PBS was introduced into the
nares under light Metofane anesthesia. Under the conditions used here, this dose
represented one 50% lethal dose but induced obvious clinical signs in 100% of
inoculated naive animals.
Antibody assays. Serum samples were obtained by limited bleeding from tail
veins. Enzyme-linked immunosorbent assays (ELISAs) included gradient-puri-
fied PR/8/34 influenza virus as the antigen and horseradish peroxidase (HRP)-
conjugated goat anti-mouse immunoglobulin G (IgG) or HRP-conjugated goat
anti-mouse IgA as the second antibody. Positive controls were the H1-specific
IgG2a monoclonal antibody 37-85, produced by W. Gerhard, Wistar Institute
(34), and obtained through S. Clarke, University of North Carolina (UNC),
Chapel Hill, and an H1-specific IgA monoclonal antibody kindly supplied by P.
Small, University of Florida, Gainesville. In these ELISAs, an optical density at
450 nm (OD450) of more than 0.2 above the background (wells without serum)
was scored as positive. Preimmunization mouse sera and sera from control mice
inoculated with PBS or vector alone showed variable reactivity at a 1:50 dilution
in the influenza virus ELISA, possibly caused by nonspecific binding of sialylated
serum immunoglobulins to the influenza virus HA. Therefore, positive reactivity
at dilutions of less than 1:100 were considered background. Plaque reduction
neutralization assays were carried out essentially as described by Olmsted et al.
(27). Virus was incubated for 30 min at 378C with dilutions of serum in the
presence of 5% guinea pig serum (Cedarlane) as a source of complement,
followed by a second 30-min incubation at 378C with a 1:200 dilution of goat
antiserum to mouse immunoglobulin (Cappel). Standard plaque assay of serum-
treated virus was done on Madin-Darby canine kidney (MDCK) cells overlaid
with agarose without serum but containing trypsin (1 mg/ml). Titers represent the
highest dilution that reduced plaque number by 60%.
In situ hybridization analysis. Tissues were prepared for in situ hybridization
as described before (6, 11). Popliteal lymph nodes were taken 24 h after s.c.
inoculation with VEE vector, while heads were processed 48 h after i.n. challenge
with influenza virus, following perfusion with 4% paraformaldehyde in PBS.
Similarly sized, [35S]UTP-labeled, negative-sense riboprobes were prepared from
transcription vectors containing either the identical HA gene used in the con-
struction of the VEE HA vector, a subclone of the VEE structural genes, or a
subclone of the Epstein-Barr virus genome, obtained from N. Raab-Traub, UNC,
Chapel Hill. The lengths of the respiratory epithelial surface in coronal sections
incubated with the HA-specific riboprobe, both total length and that associated
with positive in situ signal, were measured with a Nikon FXA microscope and a
Macintosh Quadra 840 AV computer with the public-domain National Institutes
of Health (NIH) Image program (developed at the NIH and available from the
Internet by anonymous file transfer protocol [zippy.nimh.nih.gov] or on floppy
disk from National Technical Information Service, Springfield, Va. [PB95-
500195GEI]).
RESULTS
Construction of an attenuated VEE expression vector con-
taining the influenza virus HA gene. A full-length cDNA clone
of the VEE RNA genome was the basis for construction of a
panel of live, attenuated VEE vaccine candidates (8). A rep-
resentative vaccine candidate, V3014, contains two attenuating
mutations (E2 [Lys-209] and E1 [Thr-272]), is avirulent follow-
ing s.c. inoculation of adult mice, and grows to high titers in the
draining lymph node without extensive pathology (8, 11).
V3014 was converted to a replication-competent VEE vaccine
vector by placing a second copy of the 26S subgenomic RNA
promoter and a unique ClaI site at the exact 39 end of the
structural gene region. To test this vector for its ability to
express a heterologous gene, the cloned influenza virus HA
gene from strain PR/8/34 was introduced at the unique ClaI
site downstream of the second subgenomic promoter. The
influenza virus HA protein is well characterized, as is the
disease course following i.n. inoculation of mice with strain
PR/8/34 (38). Thus, this system provides (i) a mouse model for
direct assessment of the ability of the VEE vaccine vector to
induce an immune response not only to VEE proteins but also
to a heterologous protein and (ii) a challenge model in which
to test the capacity of that response to protect against influenza
virus challenge across a mucosal surface.
VEE vector virus without an insert, HA vector virus, and AH
vector virus (containing the HA gene in the noncoding orien-
tation) were produced by transfection of BHK cells with in
vitro-synthesized RNA transcripts of the appropriate cDNA
clones. Immunoprecipitation and immunocytochemistry were
used to show that authentic HA protein was synthesized in
BHK cells infected by the HA vector. HA vector-infected cells
but not cells infected with AH vector or vector alone contained
a protein that was precipitated by anti-influenza virus rabbit
polyclonal antibody (obtained from R. Webster and B. Meyer,
St. Jude Medical Center, Memphis, Tenn.) and that migrated
on sodium dodecyl sulfate (SDS)-containing polyacrylamide
gels similarly to HA protein precipitated from BHK cells in-
fected with influenza virus (data not shown). Although high
levels of HA were produced in HA vector-infected cells, VEE
virions produced by these cells contained no detectable HA
protein (data not shown). Immunocytochemical staining with
an HA-specific monoclonal antibody (34) demonstrated that
the amount and intracellular location of HA were similar for
HA vector-infected BHK cells and influenza virus-infected
cells (data not shown). Cells infected with VEE vector alone
did not bind the HA-specific monoclonal antibody. About one-
fourth of the HA vector-infected cells (estimated from the
proportion of cells reacting with anti-VEE antibody) did not
react with the anti-HA monoclonal antibody. This may reflect
a lower detection limit for the polyclonal anti-VEE antibody
than for the HA monoclonal antibody or indicate that the HA
gene was not expressed in all HA vector-infected cells. The
possibility that the large HA gene (1.7 kb) was deleted from
the VEE vector during vector replication in some cells is sug-
gested by results with some large inserts in the analogous
Sindbis virus vector system (13).
Expression of HA in draining lymph nodes of HA vector-
inoculated mice. The major site of replication of the parent
attenuated virus, V3014, in CD-1 mice inoculated in the rear
footpad is the draining popliteal lymph node (11). V3014 does
not cause significant tissue destruction in the lymph node,
although it replicates to titers equivalent to those of its virulent
progenitor within 24 h postinfection. To determine whether
the VEE double promoter vector replicated and expressed a
heterologous gene at this site, popliteal lymph nodes taken
from mice 24 h after a primary inoculation in the rear footpads
with 23 104 PFU of either vector alone or the HA vector were
analyzed for the presence of virus-specific RNA by in situ
hybridization. The lymph node from the HA vector-inoculated
mouse bound both the VEE- and HA-specific negative-sense
riboprobes, whereas the tissue from animals inoculated with
vector alone bound only the VEE riboprobe (Fig. 1). No signal
was detected in any of the negative controls, which included
similar sections from these lymph nodes incubated with an
irrelevant, similarly sized riboprobe containing Epstein-Barr
virus sequences and lymph node sections from mock-inocu-
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lated mice incubated with all of the riboprobes. In situ hybrid-
ization analysis of spleen and decalcified legs taken at 24 h
postinoculation with the HA vector also showed specific hy-
bridization with both the HA and VEE riboprobes, while par-
allel preparations from mice inoculated with vector alone re-
acted only with the VEE riboprobe (not shown). Therefore, as
predicted from the phenotype of the attenuated VEE parent,
the VEE HA vector replicated at the site of inoculation, in the
draining lymph node, and to a lesser degree in the spleen and
expressed the inserted HA gene at all of these sites.
Anti-HA antibody levels in serum of VEE vector-immunized
mice. A correlation between the presence of anti-influenza
virus antibody in serum and protection of mice against influ-
enza virus-induced pneumonitis and death has been shown
previously (for an example, see reference 31). The delivery of
HA to the lymphoid tissues of the HA vector-immunized mice
was effective in eliciting a measurable humoral immune re-
sponse to HA. Groups of 12 6-week-old mice were given a
primary immunization by s.c. inoculation of 2 3 104 PFU of
vector alone or HA vector or an equal volume of diluent into
the rear footpads and 3 weeks later were given s.c. booster
inoculations. The boosters contained, for both vector- and HA
vector-immunized mice, 10 times the original dose of virus, or
2 3 105 PFU. Sera collected pre-immunization, 3 weeks fol-
lowing the primary immunization, and 12 days after the
booster immunization were tested by ELISA for anti-HA se-
rum IgG and IgA. After a single inoculation, 75% of the HA
vector-inoculated mice had positive anti-influenza virus serum
IgG titers, and 25% had positive anti-influenza virus serum
IgA titers (Table 1). The booster inoculation increased these
titers and gave a 100% positive response for IgG and a 75%
positive response for IgA. Inoculation with vector alone or HA
vector induced a strong primary anti-VEE humoral antibody
response (Table 1). Although the vigorous anti-VEE immune
response probably limited the replication of the booster inoc-
ulum, sufficient HA protein was expressed from the second
inoculum of HA vector to increase the anti-influenza virus
titers substantially (Table 1).
Serum samples taken 12 days after the booster immuniza-
tion were also tested for neutralizing activity against the PR/
FIG. 1. Detection of coding-sense HA RNA sequences in the popliteal lymph nodes of mice inoculated with the HA vector. Popliteal lymph nodes from mice
inoculated with vector alone (A and C) or HA vector (B and D) were harvested at 24 h postinoculation and processed for in situ hybridization. Similar sections were
probed with a 35S-labeled HA-specific riboprobe (A and B) or a 35S-labeled VEE-specific riboprobe (C and D). Magnification, 3183. Bars, 100 mm.




IgG IgA IgG IgA
Post-primary inoculation 270 126 16,000 6,600
Postboost 562 467 25,400 8,980
a Geometric mean titers for samples giving an OD450 of $0.2 at dilutions of
1:100 or greater. Preimmunization titers were consistently ,100. Of 24 animals
in the control groups, 22 had anti-HA serum IgG and IgA titers of,100, one had
an IgG titer of 100 before but not after the boost, and one had an IgA titer of 100
following the boost.
bMean anti-VEE titers for mice immunized with the HA vector (shown here)
or vector alone (not shown) were not significantly different from each other
(Student’s t test; P values ranged from 0.11 to 0.94).
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8/34 strain of influenza virus in a plaque reduction assay. Sera
from mice in the two control groups (those inoculated with
diluent or with vector alone) did not neutralize influenza virus
at a dilution of 1:20, the lowest tested. However, all sera from
the HA vector-immunized mice showed neutralizing activity.
Ten of the 12 sera from this group gave a geometric mean 60%
plaque reduction titer of 1,175, while samples from 2 of the 12
mice showed 30 and 56% plaque reduction at the lowest dilu-
tion. As a benchmark comparison, convalescent-phase sera (post-
challenge sera from four surviving mock-immunized mice)
gave a geometric mean 60% plaque reduction titer of 460.
Protection of HA vector-immunized mice against intranasal
challenge. (i) Protection from clinical disease. Three weeks
after receiving a single s.c. dose of diluent, 2 3 104 PFU of
vector alone, or 2 3 104 PFU of HA vector, mice were chal-
lenged i.n. with influenza virus strain PR/8/34, a strain that
induces a lethal pneumonitis in mice infected by this route
(38). Results recorded over a 2-week observation period
showed that inoculation with the HA vector conferred signif-
icant protection against mortality (P , 0.01) and morbidity
(P , 1024). Mice in the two control groups suffered 54%
mortality overall, and all of the survivors showed moderate to
severe signs of disease for an average of 5.1 6 1.9 days. In
contrast, 7 of 12 immunized animals showed no signs of infec-
tion, and 3 other animals showed very mild signs for an average
of 2.3 6 1.2 days. One HA vector-immunized mouse died, and
one showed severe signs for 1 day prior to recovery. These two
individuals had undetectable anti-influenza virus serum IgG
prior to challenge.
In a separate experiment, three groups of 12 mice received
both a primary and booster immunization of either vector alone
or HA vector or were mock immunized with diluent (antibody
titers in Table 1). At 18 days following the boost, these mice
were challenged i.n. with influenza virus strain PR/8/34. Four
mice in each group were sacrificed at 48 h postchallenge for in
situ hybridization analysis of nasal tissue (see below). For the
remaining mice, results recorded over a 22-day observation
period showed that immunization with the HA vector con-
ferred complete protection against mortality and morbidity
(Fig. 2). Mice in the two control groups suffered 44% mortality
overall, and all of the survivors showed clinical signs of disease
for an average of 4.3 6 1.7 days. In contrast, none of the HA
vector-immunized animals died or showed any clinical signs of
disease.
Protection of HA vector-immunized mice against illness was
also indicated by individual daily weight measurements. Mice
receiving two inoculations of diluent or vector alone showed
an average maximum weight loss (percent of initial weight) of
23.4 6 5.6% and 26.0 6 11.2%, respectively, while mice im-
munized twice with HA vector lost only 8.4 6 5.0%. By 9
days postchallenge, HA vector-immunized mice on average
had recovered their initial weight, while surviving mice that
had received diluent or vector alone still weighed an average
of 19.5 6 6.2 and 21.7 6 6.2% less than their initial weights,
respectively.
As would be predicted from previous results with V3014 and
other attenuated VEE strains (7, 8, 16, 17), mice inoculated
with a single s.c. dose of 2 3 104 PFU of vector alone or HA
vector were completely protected against VEE-induced dis-
ease following either intraperitoneal or i.n. lethal challenge
with 104 PFU of virulent VEE (data not shown).
(ii) Restriction of challenge virus replication in vivo. Par-
enteral immunization with the HA vector also reduced the
level of influenza virus replication in the lung (Fig. 3). Mice
received a single s.c. inoculation of vector alone, HA vector, or
diluent and were challenged i.n. with virulent influenza virus 3
FIG. 2. Protection resulting from primary and booster immunizations with
VEE HA vector against i.n. challenge with virulent influenza virus. Mice received
primary and booster inoculations of diluent (A), vector alone (B), or HA vector
(C), were challenged i.n. with influenza virus PR/8/34 at 18 days following the
boost, and were observed for 22 days. Open bars, clinically normal mice; solid
bars, dead mice. Mildly affected mice showed slight ruffling (open hatching).
Moderately ill mice showed ruffling, hunching, and slowed movement (dense
hatching). Severely ill mice showed lack of movement, obvious wasting, and
labored breathing (crosshatching).
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weeks later. At 4 days postchallenge, no influenza virus was
detected in the lungs of 12 HA vector-immunized mice. Eight
of 12 diluent controls and 5 of 12 vector-alone controls were
positive for influenza virus replication in the lungs, with geo-
metric mean titers of 3.0 3 106 and 1.9 3 106 PFU/g, respec-
tively.
Replication of the challenge virus in the nasal epithelium
was measured directly by in situ hybridization with an HA-
specific riboprobe. Mice were immunized with primary and
booster doses of vector alone or HA vector, or mock immu-
nized, and challenged i.n. with virulent influenza virus as de-
scribed above. Forty-eight hours after challenge, the animals
were killed, and the heads were prepared and sectioned for in
situ hybridization (6). Four mice were selected from each
group. With the serum neutralizing antibody level used as a
general indicator of the overall HA-specific response, HA vec-
tor-immunized mice with different intensities of response were
chosen. One in situ sample was from the HA vector-immu-
nized mouse with the lowest level of serum neutralizing anti-
body and minimal reactivity in ELISA, while the other three
mice had 60% plaque reduction neutralizing titers of 500,
1,000, and 5,000. Intense confluent stretches of positive in situ
signal marked the epithelial surface of the upper respiratory
tract in sections from mice inoculated with vector alone or
diluent (Fig. 4A), indicating vigorous replication and cell-to-
cell spread of the challenge virus. In contrast, sections from
HA vector-immunized mice showed fewer and smaller foci of
positive in situ signal (Fig. 4B), indicating restriction of repli-
cation and limitation of spread of the challenge virus.
A morphometric analysis of the coronal sections used for in
situ hybridization was performed to compare the percentage of
the upper respiratory epithelial surface that bound the HA
riboprobe among animals in the three groups. The mean per-
centage for the combined control groups was 16.21 6 5.43%.
This value and the percentages for individual HA vector-im-
munized mice were compared with respect to their corre-
sponding serum neutralizing antibody titers (Fig. 4C). The
upper respiratory tract epithelium from the HA vector-immu-
nized mouse with the lowest neutralizing antibody titer (,20)
was among the least resistant to replication of the challenge
FIG. 3. Restriction of influenza virus replication in lungs of HA vector-
immunized mice. Mice were inoculated s.c. with diluent, vector alone, or HA
vector and 26 days later were challenged i.n. with influenza virus PR/8/34. Mice
were killed on day 4 postchallenge, and lungs were homogenized in PBS with
0.1% (wt/vol) bovine serum albumin to give a 20% (wt/vol) suspension, clarified
by centrifugation, and stored at 2708C. A standard plaque assay on MDCK cells
was performed with duplicate aliquots. The limit of detection was approximately
25 PFU per average lung. Geometric mean titers (solid circles) were calculated
for control mice with measurable virus titers.
FIG. 4. Detection of HA mRNA sequences in the nasal epithelia of mice
challenged i.n. with virulent influenza virus. Mice were immunized and chal-
lenged as described in the legend to Fig. 2. At 48 h postchallenge, heads were
processed for in situ hybridization. (A and B) Coronal sections from mice
inoculated with diluent (A) or HA vector (B) were incubated with a 35S-labeled,
negative-sense HA-specific riboprobe. The percent respiratory surface involved
for the HA vector-immunized mouse (B) was 4.7%, similar to the average of
3.65% for mice with a strong anti-HA immune response. No signal was detected
in similar sections incubated with a VEE virus-specific riboprobe. Magnification,
3123. Bar, 100 mm. (C) Percent respiratory surface involved (the length of
respiratory surface in each section showing positive in situ signal divided by the
total length 3 100) was calculated for individual HA vector-immunized mice
(solid bars), averaged for controls (open bar), and plotted relative to titers of
anti-influenza virus neutralizing antibody.
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influenza virus, while sections from the three mice with strong
anti-HA immune responses showed a significant reduction in
the extent of challenge virus replication (mean percentage,
3.65 6 3.12%). Therefore, successful immunization with the
HA vector, indicated by high levels of anti-HA serum neutral-
izing antibody, conferred significant protection against repli-
cation of virulent influenza virus in the target cells of the upper
respiratory mucosa. In a separate experiment with mice immu-
nized only once with vector alone or HA vector, the combined
percentage of upper respiratory epithelial involvement was
reduced by greater than 50% in the HA vector-immunized
mice (data not shown). These results show that the protective
effect of a parenteral immunization with the HA vector ex-
tended to a vulnerable mucosal surface. The immunological
mediators of that protection remain to be determined but are
presumed to include HA-specific antibody at the mucosal sur-
face.
DISCUSSION
The properties of VEE vaccine strains in humans and in
rodent models predicted two characteristics of a VEE vaccine
vector expressing a heterologous gene. The first prediction was
that a heterologous gene would be expressed in the lymph
node draining the site of inoculation, based on the finding that
the parental VEE strain and its attenuated mutant, V3014,
replicate extensively at this site. In work presented here, we
showed that the HA vector, derived from V3014, also repli-
cated and expressed the HA gene in lymph nodes, a site ex-
pected to favor the efficient induction of an immune response.
In fact, the average level of anti-influenza virus serum neutral-
izing antibody induced by the VEE HA vector was in excess of
that found among control animals that survived influenza vi-
rus-induced disease.
The second prediction was that protection against challenge
at a mucosal surface would be evident even when the VEE
vaccine was administered parenterally. Live attenuated VEE
vaccines can induce protection against i.n. or aerosol challenge
regardless of the route of administration. Protection against
disease caused by virus invasion across a mucosal surface may
occur either at the level of the mucosal surface itself, by pre-
venting the initial infection of epithelial target cells, or at a
later step, by preventing spread of the virus and the resulting
clinical signs. In work not presented here, s.c. immunization of
mice with V3014 induced a vigorous humoral antibody re-
sponse, substantial anti-VEE IgA on the vaginal surface, de-
tectable anti-VEE IgA in nasal secretions, and complete pro-
tection of the nasal neuroepithelium from infection following
i.n. challenge with virulent VEE virus (5). This represents a
case in which specific antibodies are detected both in the serum
and at the mucosa and strong protective immunity is observed
at the level of the mucosal surface. Likewise, we have now
demonstrated that immunization with the HA vector derived
from V3014 provided significant protection at the level of the
nasal mucosa upon i.n. influenza virus challenge. When effec-
tive protection is observed at the level of the mucosal surface,
it may involve one or more distinct elements, including secre-
tory IgA antibody, transudated humoral IgA and/or IgG anti-
bodies, or a specific cellular immune response (reviewed in
reference 26). Although the exact contribution of each element
of the immune response to this protection remains to be de-
termined, we have detected low levels of HA-specific IgA in
vaginal wash samples from mice immunized by s.c. inoculation
with the HA vector (unpublished results).
As might be expected for a virus with a highly structured
icosahedral capsid (35), there is a limit to the amount of het-
erologous genetic material that can be stably accommodated in
the alphavirus genome. Our results suggest that a proportion
of HA vector viruses lose the property of HA expression dur-
ing successive rounds of replication in cultured cells. However,
other inserted genes, not described here, are more stably ex-
pressed from this vector (4). It appears that multiple factors,
including but not limited to the length of the heterologous
sequence, determine stability of expression. The HA protein
may be unusually detrimental to VEE replication, which in-
creases the selective pressure for its deletion. Therefore, re-
sults with the HA gene may represent a minimal estimate of
the immunizing efficacy of VEE vaccine vectors.
The influenza virus challenge model in mice was used here
as a feasibility test for protective immunization with replica-
tion-competent VEE vaccine vectors. There is good potential
for human use of an attenuated VEE vaccine configured as a
vaccine vector, based on long experience with an investiga-
tional live attenuated VEE vaccine (TC-83), the only such
alphavirus vaccine tested extensively in humans (3). More re-
cent recombinant live attenuated VEE vaccine candidates are
superior to TC-83 in both safety and efficacy in rodents (8),
horses (1), and primates (30). Unintentional spread of an en-
gineered VEE strain by the mosquito vector, an important
safety issue, is made extremely unlikely in that V3014, the
attenuated parent of the vector described here, does not pro-
duce a serum viremia in rodents (11), and even the virulent
Trinidad donkey strain of VEE produces a viremia in humans
that is too low to support transmission by mosquitoes (33).
Other attenuating mutations under consideration appear to
reduce specifically the efficiency of transmission by the mos-
quito vector (36).
Engineering live virus vaccines for immunization against
heterologous antigens is an active area of experimentation. To
this end, expression of foreign genes has been accomplished
with members of several virus families, e.g., poxviruses, adeno-
viruses, picornaviruses, herpesviruses, and orthomyxoviruses,
as well as alphaviruses (reviewed in reference 32). In fact, it is
very unlikely that one vector system will be optimal in all
respects, such as the length of heterologous sequence that can
be maintained stably in the vector, level of efficacy, induction
of mucosal protection, potential problems associated with pre-
existing immunity to the vector, and issues of safety, such as the
potential for latent infection. Moreover, the generation of a
strong immune response to the vector itself will allow only a
limited number of applications of a specific vaccine vector in a
given population. Therefore, efforts to produce an ideal vector
for all applications are likely to be unproductive. Rather, a
strong case can be made for parallel development of multiple
virus vaccine vectors, including VEE, which will make available
the unique advantages of each for specific applications.
In summary, we have described the generation of a replica-
tion-competent VEE expression vector capable of driving the
efficient synthesis of a heterologous protein in cell culture and
in vivo. This vector replicated in lymphoid tissue draining the
s.c. inoculation site, where it expressed an inserted influenza
virus HA gene. The resulting immune response was character-
ized by high levels of anti-HA serum antibody. Following i.n.
challenge with virulent influenza virus, we observed complete
protection against clinical signs of disease, restriction of chal-
lenge virus replication in the lungs, and significant protection
of the nasal mucosal surfaces. These findings suggest that a
new generation of rationally engineered, molecularly cloned
live VEE vaccines may serve as effective and safe vaccine
vectors, protecting against systemic and mucosal pathogens for
which other vaccine strategies are not effective or feasible.
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